Paratek also announced its full-year 2023 revenue guidance, which is expected to be in the range of $143.0 to $158.0 million, which includes the following components: NUZYRA net U.S. sales of approximately $125.0 to $135.0 million. BARDA government contract service and grant revenue between $15.0 to $20.0 million. Royalty and collaboration revenue of approximately $3.0 million. Paratek expects to reduce full-year 2023 R&D and SG&A expense below that incurred in 2022.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
- Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Paratek announces inclusion of NUZRYA in China’s NRDL
- Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
